Published in Biol Psychiatry on October 06, 2009
A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans. Am J Psychiatry (2014) 4.25
Excessive discounting of delayed reinforcers as a trans-disease process contributing to addiction and other disease-related vulnerabilities: emerging evidence. Pharmacol Ther (2012) 2.98
Uncertainty and anticipation in anxiety: an integrated neurobiological and psychological perspective. Nat Rev Neurosci (2013) 2.23
Fear conditioning, synaptic plasticity and the amygdala: implications for posttraumatic stress disorder. Trends Neurosci (2011) 2.12
D-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder. Am J Psychiatry (2013) 1.94
D-cycloserine effects on extinction of conditioned responses to drug-related cues. Biol Psychiatry (2012) 1.72
Implications of memory modulation for post-traumatic stress and fear disorders. Nat Neurosci (2013) 1.72
Acute shift in glutamate concentrations following experimentally induced panic with cholecystokinin tetrapeptide--a 3T-MRS study in healthy subjects. Neuropsychopharmacology (2013) 1.67
Psychological treatments: A call for mental-health science. Nature (2014) 1.66
Glutamate receptors in extinction and extinction-based therapies for psychiatric illness. Neuropsychopharmacology (2010) 1.51
Effects of post-session administration of methylene blue on fear extinction and contextual memory in adults with claustrophobia. Am J Psychiatry (2014) 1.48
D-cycloserine deters reacquisition of cocaine self-administration by augmenting extinction learning. Neuropsychopharmacology (2010) 1.46
Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry (2014) 1.39
Fear extinction and BDNF: translating animal models of PTSD to the clinic. Genes Brain Behav (2012) 1.31
Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. Nat Rev Drug Discov (2013) 1.27
D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia. Biol Psychiatry (2013) 1.26
Pharmacological treatment of PTSD - established and new approaches. Neuropharmacology (2011) 1.24
A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry (2010) 1.20
D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial. Neuropsychopharmacology (2013) 1.18
NMDA receptors and fear extinction: implications for cognitive behavioral therapy. Dialogues Clin Neurosci (2011) 1.17
Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders. Front Neurosci (2013) 1.16
D-cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions. J Psychiatr Res (2013) 1.09
Augmentation of exposure therapy with post-session administration of D-cycloserine. J Psychiatr Res (2012) 1.06
Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia. Drug Discov Today (2009) 1.05
Cognitive enhancers for anxiety disorders. Pharmacol Biochem Behav (2010) 1.04
D-cycloserine augmentation of cognitive behavioral group therapy of social anxiety disorder: prognostic and prescriptive variables. J Consult Clin Psychol (2013) 1.04
How to erase memory traces of pain and fear. Trends Neurosci (2013) 1.03
BDNF function as a potential mediator of bipolar disorder and post-traumatic stress disorder comorbidity. Mol Psychiatry (2011) 1.02
Behavioral and neurobiological mechanisms of extinction in Pavlovian and instrumental learning. Neurobiol Learn Mem (2013) 1.02
Cognitive enhancers for facilitating drug cue extinction: insights from animal models. Pharmacol Biochem Behav (2011) 1.00
Pharmacological enhancement of fear reduction: preclinical models. Br J Pharmacol (2011) 0.99
D-Cycloserine as an augmentation strategy for cognitive behavioral therapy of anxiety disorders. Biol Mood Anxiety Disord (2013) 0.98
Therapygenetics: moving towards personalized psychotherapy treatment. Trends Cogn Sci (2011) 0.97
D-cycloserine augmentation of behavioral therapy for the treatment of anxiety disorders: a meta-analysis. J Clin Psychiatry (2012) 0.95
Does maintenance CBT contribute to long-term treatment response of panic disorder with or without agoraphobia? A randomized controlled clinical trial. J Consult Clin Psychol (2012) 0.95
Chronic antidepressant treatment impairs the acquisition of fear extinction. Biol Psychiatry (2012) 0.93
An Overview of Translationally Informed Treatments for Posttraumatic Stress Disorder: Animal Models of Pavlovian Fear Conditioning to Human Clinical Trials. Biol Psychiatry (2015) 0.92
Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders. Pharmacol Ther (2014) 0.92
Does D-cycloserine enhance exposure therapy for anxiety disorders in humans? A meta-analysis. PLoS One (2014) 0.90
Pharmacological enhancement of drug cue extinction learning: translational challenges. Ann N Y Acad Sci (2011) 0.90
A pilot study of the effectiveness of D-cycloserine during cue-exposure therapy in abstinent alcohol-dependent subjects. Psychopharmacology (Berl) (2011) 0.89
Pharmacological enhancement of exposure-based treatment in PTSD: a qualitative review. Eur J Psychotraumatol (2013) 0.88
Effect of D-cycloserine and valproic acid on the extinction of reinstated fear-conditioned responses and habituation of fear conditioning in healthy humans: a randomized controlled trial. Psychopharmacology (Berl) (2011) 0.85
A controlled trial of the adjunct use of D-cycloserine to facilitate cognitive behavioral therapy outcomes in a cocaine-dependent population. Addict Behav (2012) 0.84
Reward learning as a potential target for pharmacological augmentation of cognitive remediation for schizophrenia: a roadmap for preclinical development. Front Neurosci (2013) 0.83
Combining d-cycloserine with motor training does not result in improved general motor learning in neurologically intact people or in people with stroke. J Neurophysiol (2014) 0.83
Etiology, triggers and neurochemical circuits associated with unexpected, expected, and laboratory-induced panic attacks. Neurosci Biobehav Rev (2014) 0.82
Enhancing exposure therapy for anxiety disorders, obsessive-compulsive disorder and post-traumatic stress disorder. Expert Rev Neurother (2014) 0.82
Tau-mediated NMDA receptor impairment underlies dysfunction of a selectively vulnerable network in a mouse model of frontotemporal dementia. J Neurosci (2014) 0.82
D-cycloserine to enhance extinction of cue-elicited craving for alcohol: a translational approach. Transl Psychiatry (2015) 0.81
Enhancement of Psychosocial Treatment With D-Cycloserine: Models, Moderators, and Future Directions. Biol Psychiatry (2015) 0.79
Pharmacological enhancement of mGluR5 facilitates contextual fear memory extinction. Learn Mem (2014) 0.79
Advances in the treatment of pediatric obsessive-compulsive d-cycloserine with exposure and response prevention. Neuropsychiatry (London) (2012) 0.79
Does d-Cycloserine Augmentation of CBT Improve Therapeutic Homework Compliance for Pediatric Obsessive-Compulsive Disorder? J Child Fam Stud (2014) 0.79
Interoception and learning: import to understanding and treating diseases and psychopathologies. ACS Chem Neurosci (2014) 0.79
A high-throughput clinical assay for testing drug facilitation of exposure therapy. Depress Anxiety (2013) 0.78
Antianxiety medications for the treatment of complex agoraphobia: pharmacological interventions for a behavioral condition. Neuropsychiatr Dis Treat (2011) 0.78
A novel treatment for tinnitus and tinnitus-related cognitive difficulties using computer-based cognitive training and D-cycloserine. JAMA Otolaryngol Head Neck Surg (2015) 0.77
D-cycloserine augmentation in behavioral therapy for obsessive-compulsive disorder: a meta-analysis. Drug Des Devel Ther (2015) 0.77
Effects of D-amino acid oxidase inhibition on memory performance and long-term potentiation in vivo. Pharmacol Res Perspect (2013) 0.77
The Future of D-Cycloserine and Other Cognitive Modifiers in Obsessive-Compulsive and Related Disorders. Curr Psychiatry Rev (2014) 0.77
The effect of D-cycloserine on subliminal cue exposure in spider fearful individuals. Cogn Behav Ther (2012) 0.76
Dose timing of D-cycloserine to augment cognitive behavioral therapy for social anxiety: Study design and rationale. Contemp Clin Trials (2015) 0.76
Genome-wide association study of NMDA receptor coagonists in human cerebrospinal fluid and plasma. Mol Psychiatry (2015) 0.76
Neuroenhancement of Exposure Therapy in Anxiety Disorders. AIMS Neurosci (2015) 0.75
The Efficacy of Augment of D-Cycloserine and Cognitive-behavioral Therapy on Adolescent with one Type of Anxiety Disorders: A Double-blind Randomized Controlled Trial. Adv Biomed Res (2017) 0.75
D-cycloserine augmentation of behavior therapy for anxiety and obsessive-compulsive disorders: A meta-analysis. PLoS One (2017) 0.75
Novel approaches in treatment of pediatric anxiety. F1000Prime Rep (2014) 0.75
Baseline psychophysiological and cortisol reactivity as a predictor of PTSD treatment outcome in virtual reality exposure therapy. Behav Res Ther (2016) 0.75
Successful pharmacotherapy for the treatment of severe feeding aversion with mechanistic insights from cross-species neuronal remodeling. Transl Psychiatry (2017) 0.75
Emerging drugs for the treatment of anxiety. Expert Opin Emerg Drugs (2015) 0.75
Parents' Perceptions of Novel Treatments for Child and Adolescent Specific Phobia and Anxiety Disorders. Child Psychiatry Hum Dev (2016) 0.75
Emotional Modulation of Learning and Memory: Pharmacological Implications. Pharmacol Rev (2017) 0.75
D-cycloserine improves synaptic transmission in an animal mode of Rett syndrome. PLoS One (2017) 0.75
DtiStudio: resource program for diffusion tensor computation and fiber bundle tracking. Comput Methods Programs Biomed (2006) 7.65
Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull (2003) 7.11
Aberrant "default mode" functional connectivity in schizophrenia. Am J Psychiatry (2007) 7.08
Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry (2004) 6.05
A method for functional network connectivity among spatially independent resting-state components in schizophrenia. Neuroimage (2007) 4.89
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov (2008) 4.46
Social supports and serotonin transporter gene moderate depression in maltreated children. Proc Natl Acad Sci U S A (2004) 4.42
A baseline for the multivariate comparison of resting-state networks. Front Syst Neurosci (2011) 4.16
Modulation of temporally coherent brain networks estimated using ICA at rest and during cognitive tasks. Hum Brain Mapp (2008) 3.98
Brain-derived neurotrophic factor-5-HTTLPR gene interactions and environmental modifiers of depression in children. Biol Psychiatry (2006) 3.97
Imaging cortical association tracts in the human brain using diffusion-tensor-based axonal tracking. Magn Reson Med (2002) 3.67
Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry (2004) 3.64
Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry (2008) 3.63
Temporal lobe and "default" hemodynamic brain modes discriminate between schizophrenia and bipolar disorder. Hum Brain Mapp (2008) 3.54
Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med (2011) 3.36
A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder. Am J Psychiatry (2014) 3.27
Telomere shortening and mood disorders: preliminary support for a chronic stress model of accelerated aging. Biol Psychiatry (2006) 2.85
Different activation dynamics in multiple neural systems during simulated driving. Hum Brain Mapp (2002) 2.80
Psychological treatments for fibromyalgia: a meta-analysis. Pain (2010) 2.78
Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry (2006) 2.77
Mindfulness-based therapy: a comprehensive meta-analysis. Clin Psychol Rev (2013) 2.75
A prospective cohort study investigating factors associated with depression during medical internship. Arch Gen Psychiatry (2010) 2.41
The role of default network deactivation in cognition and disease. Trends Cogn Sci (2012) 2.39
Abnormal functional connectivity of default mode sub-networks in autism spectrum disorder patients. Neuroimage (2010) 2.38
A functional magnetic resonance imaging study of bipolar disorder: state- and trait-related dysfunction in ventral prefrontal cortices. Arch Gen Psychiatry (2003) 2.36
Effects of smoking and smoking abstinence on cognition in adolescent tobacco smokers. Biol Psychiatry (2005) 2.36
Association between alcoholism and gamma-amino butyric acid alpha2 receptor subtype in a Russian population. Alcohol Clin Exp Res (2005) 2.35
Differences in resting-state functional magnetic resonance imaging functional network connectivity between schizophrenia and psychotic bipolar probands and their unaffected first-degree relatives. Biol Psychiatry (2012) 2.33
The liebowitz social anxiety scale as a self-report instrument: a preliminary psychometric analysis. Behav Res Ther (2002) 2.29
Morphometric assessment of the heteromodal association cortex in schizophrenia. Am J Psychiatry (2004) 2.27
A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry (2008) 2.17
Individuals family history positive for alcoholism show functional magnetic resonance imaging differences in reward sensitivity that are related to impulsivity factors. Biol Psychiatry (2010) 2.16
Amygdala and hippocampal volumes in adolescents and adults with bipolar disorder. Arch Gen Psychiatry (2003) 2.15
Diffusion tensor imaging in schizophrenia. Biol Psychiatry (2005) 2.14
Alcohol intoxication effects on simulated driving: exploring alcohol-dose effects on brain activation using functional MRI. Neuropsychopharmacology (2004) 2.12
Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia. J Clin Psychiatry (2012) 2.10
Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry (2004) 2.04
Changes in the interaction of resting-state neural networks from adolescence to adulthood. Hum Brain Mapp (2009) 2.01
Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study. Arch Gen Psychiatry (2002) 2.01
Gender differences in anxiety disorders: prevalence, course of illness, comorbidity and burden of illness. J Psychiatr Res (2011) 2.00
Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry (2002) 1.99
Effects of suppression and acceptance on emotional responses of individuals with anxiety and mood disorders. Behav Res Ther (2005) 1.97
Altered NMDA glutamate receptor antagonist response in individuals with a family vulnerability to alcoholism. Am J Psychiatry (2004) 1.96
D-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder. Am J Psychiatry (2013) 1.94
Cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected injection drug users: a randomized controlled trial. J Consult Clin Psychol (2012) 1.94
Hypnotic enhancement of cognitive-behavioral interventions for pain: an analogue treatment study. Health Psychol (2003) 1.93
Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis. Drug Saf (2009) 1.91
The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging Behav (2014) 1.90
Investigating the behavioral and self-report constructs of impulsivity domains using principal component analysis. Behav Pharmacol (2009) 1.90
Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Alcohol Clin Exp Res (2007) 1.86
Functional neural networks underlying response inhibition in adolescents and adults. Behav Brain Res (2007) 1.85
Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. Am J Psychiatry (2013) 1.85
Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative. Biol Psychiatry (2008) 1.81
Transcranial magnetic stimulation of left temporoparietal cortex and medication-resistant auditory hallucinations. Arch Gen Psychiatry (2003) 1.81
The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res (2011) 1.80
Neuropsychological functioning in bipolar disorder and schizophrenia. Biol Psychiatry (2006) 1.80
Clinical phenotypes of psychosis in the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP). Am J Psychiatry (2013) 1.76
Rare nonsynonymous variants in alpha-4 nicotinic acetylcholine receptor gene protect against nicotine dependence. Biol Psychiatry (2011) 1.76
Impairment of working memory maintenance and response in schizophrenia: functional magnetic resonance imaging evidence. Biol Psychiatry (2008) 1.76
Cross-cultural differences in somatic presentation in patients with generalized anxiety disorder. J Nerv Ment Dis (2006) 1.76
Quality of life in the anxiety disorders: a meta-analytic review. Clin Psychol Rev (2007) 1.75
Abnormal hemodynamics in schizophrenia during an auditory oddball task. Biol Psychiatry (2005) 1.72
A method for evaluating dynamic functional network connectivity and task-modulation: application to schizophrenia. MAGMA (2010) 1.70
Frontostriatal abnormalities in adolescents with bipolar disorder: preliminary observations from functional MRI. Am J Psychiatry (2003) 1.70
Voxel-based morphometry versus region of interest: a comparison of two methods for analyzing gray matter differences in schizophrenia. Schizophr Res (2005) 1.69
A functional MRI study of amygdala responses to angry schematic faces in social anxiety disorder. Depress Anxiety (2008) 1.68
Why Do People Use Facebook? Pers Individ Dif (2011) 1.67
Impaired visual cortical plasticity in schizophrenia. Biol Psychiatry (2012) 1.67
Preliminary evidence for medication effects on functional abnormalities in the amygdala and anterior cingulate in bipolar disorder. Psychopharmacology (Berl) (2005) 1.67
Rare ADH variant constellations are specific for alcohol dependence. Alcohol Alcohol (2012) 1.66
Aberrant localization of synchronous hemodynamic activity in auditory cortex reliably characterizes schizophrenia. Biol Psychiatry (2004) 1.65
Increased cortical GABA concentrations in depressed patients receiving ECT. Am J Psychiatry (2003) 1.64
Nicotine effects on brain function and functional connectivity in schizophrenia. Biol Psychiatry (2004) 1.64
Global prefrontal and fronto-amygdala dysconnectivity in bipolar I disorder with psychosis history. Biol Psychiatry (2012) 1.62
Ketamine and the potential role for rapid-acting antidepressant medications. Swiss Med Wkly (2007) 1.62
Screening for social anxiety disorder with the self-report version of the Liebowitz Social Anxiety Scale. Depress Anxiety (2009) 1.61
The Disgust Scale: item analysis, factor structure, and suggestions for refinement. Psychol Assess (2007) 1.60
Genetic and environmental predictors of early alcohol use. Biol Psychiatry (2006) 1.60
Acceptability and suppression of negative emotion in anxiety and mood disorders. Emotion (2006) 1.58
A functional magnetic resonance imaging study of working memory abnormalities in schizophrenia. Biol Psychiatry (2006) 1.56
An ICA-based method for the identification of optimal FMRI features and components using combined group-discriminative techniques. Neuroimage (2009) 1.56
Extracellular metabolites in the cortex and hippocampus of epileptic patients. Ann Neurol (2005) 1.55
Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biol Psychiatry (2005) 1.55
Glutamate metabolism in major depressive disorder. Am J Psychiatry (2014) 1.52
Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry (2005) 1.52
Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting. Schizophr Bull (2008) 1.52
Comorbidity in hoarding disorder. Depress Anxiety (2011) 1.52
Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry (2006) 1.51
An initial study of neural responses to monetary incentives as related to treatment outcome in cocaine dependence. Biol Psychiatry (2011) 1.50
A randomized placebo-controlled trial of D-cycloserine and exposure therapy for posttraumatic stress disorder. J Psychiatr Res (2012) 1.50
Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans. Schizophr Bull (2012) 1.50